Combination of pure 5-HT6 receptor antagonists with acetylcholinesterase inhibitors
AssigneeSuven Life Sciences Limited
InventorsRamakrishna Nirogi, Anil Karbhari Shinde, Pradeep Jayarajan, Gopinadh Bhyrapuneni, Ramasastri Kambhampati, Venkateswarlu Jasti
Life of this patent
Estimating the term…
Abstract
The present invention relates to pure 5-HT6 receptor antagonists, or the pharmaceutically acceptable salt(s) thereof in combination with or as adjunct to acetylcholinesterase inhibitors and their use in the treatment of cognitive disorders. The invention further provides the pharmaceutical composition containing the said combination.
Claims38
A combination consisting essentially of a pure 5-HT6 receptor antagonist and an acetylcholinesterase inhibitor;
- wherein:
- the pure 5-HT6 receptor antagonist is selected from,
- 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
- 1-[(4-Fluorophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
- and
- 1-[(4-Isopropylphenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole;
- or a pharmaceutically acceptable salt thereof.
A method of treating Alzheimer's disease in a patient comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof and acetylcholinesterase inhibitor.
A method of treating Alzheimer's disease in a patient on stable treatment with acetylcholinesterase inhibitor comprising administering to said patient a therapeutically effective amount of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.